International Journal of Hematology

, Volume 75, Issue 1, pp 45–50 | Cite as

Prognosis of Elderly Patients With Acute Myelogenous Leukemia: Analysis of 126 AML Cases

  • Rika Iwakiri
  • Masatsugu Ohta
  • Michiaki Mikoshiba
  • Hisashi Tsutsumi
  • Toshiro Kumakawa
  • Mayumi Mori
Progress in Hematology


We retrospectively analyzed 126 acute myelogenous leukemia (AML) patients aged ≥60 years who had all been referred to the same hematological department between 1989 and 1999. In 76 de novo AML cases, 53 patients (median age, 72 years) were treated with combination chemotherapy (CT) for remission induction. Complete remission (CR) rate was 57.1%. The median overall survival (OS) was 16 months, and the rate of 3-year OS was 28%. The favorable prognostic factors were performance status ≥2, cholinesterase ≥100 IU, and intermediate or favorable karyotype (P < .01). Seventeen patients (median age, 78 years) with hypocellular bone marrow or poor general condition were treated with low-dose cytosine arabinoside (LDAraC). In these patients, the CR rate was 50% and the median OS was 11 months, with an OS estimate at 3 years of 14%. All patients with hypocellular bone marrow who received LDAraC for 21 days achieved CR. In 50 patients who developed AML following a myelodysplastic syndrome (MDS/AML), 22 patients (median age, 74 years) were treated with CT, and 14 (median age, 74 years) patients were treated with LDAraC. The CR rates were 22.7% and 21.4%, respectively, and the median OS durations were 8 months and 11 months, respectively. There were no significant factors that would indicate a good prognosis in MDS/AML patients.

Key words

Elderly AML Prognostic factor Combination chemotherapy Low-dose AraC 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brinker M. Estimate of overall treatment results in acute nonlym- phocytic leukemia based on age specific rates of incidence and of complete remission.Cancer Treat Rep. 1985;69:5–11.Google Scholar
  2. 2.
    Whitely R, Hannah P, Holmes F. Survival in acute leukemia in elderly patients. No improvement in the 1980s.J Am Geriatr Soc. 1990;38:527–530.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Arumugan M. Acute myeloblastic leukemia in the elderly: biology, prognostic factors and treatment.Int J Hematol. 1998;68:235–243.CrossRefGoogle Scholar
  4. 4.
    Heyll A, Aul C, Gogolin F, et al. Results of combination-dose cyto- sine arabinoside and idarubicin in elderly patients with acute myeloid leukemia.Ann Hematol. 1994;68:279–283.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Liu Yin JA, Johnson PR, Davies JM, Flanagan NG, Gorst DW, Lewis MJ. Mitozantrone and cytosine arabinoside as first-line therapy in elderly patients with acute myeloid leukemia.Br J Haema-tol. 1991;79:415–420.CrossRefGoogle Scholar
  6. 6.
    Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the leukemia cooperative group of European Organization for the Research and Treatment of Cancer (EORTOC-LC6) and the Dutch Belgian Hemato- Oncology Cooperative Group (HOVON).J Clin Oncol. 1997;90:2952–2961.Google Scholar
  7. 7.
    Witz F, Sadoun A, Perrin M-C, et al. A placebo-controlled study of rhGM-CSF administered during and after induction treatment for de novo AML in elderly patients.Blood. 1998;91:2722–2730.PubMedGoogle Scholar
  8. 8.
    Mitelman F, ed.An International System for Human Cytogenetics Nomenclature. Basel: Karger; 1995.Google Scholar
  9. 9.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation.J Am Stat Assoc. 1985;53:457–481.CrossRefGoogle Scholar
  10. 10.
    Baudard M, Marie JP, Cadiou M, et al. Acute myelogenous leukemia in elderly: retrospective study of 235 consecutive patients.Br J Haematol. 1994;86:82–91.CrossRefPubMedGoogle Scholar
  11. 11.
    Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in elderly: a critical review of therapeutic approaches and appraisal of results of therapy.Leukemia Lymphoma. 1998;29:375–382.CrossRefPubMedGoogle Scholar
  12. 12.
    Arlin Z, Case DC, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL).Leukemia. 1990;4:177–183.PubMedGoogle Scholar
  13. 13.
    Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in elderly: final report of the Leukemia Cooperative Group of the European Organization for the research and treatment of cancer and the Dutch-Belgian Hemato-Oncology Cooperative HOVON Group randomized phase III study AML9.J Clin Oncol. 1998;16:872–881.CrossRefPubMedGoogle Scholar
  14. 14.
    Stasi R, Venditti A, Poeta GD, et al. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia.Cancer. 1996;77:2476–2488.CrossRefPubMedGoogle Scholar
  15. 15.
    Buchner T, Hiddemann W, Loffer H, et al. Treatment of AML in the elderly full-dose versus reduced induction treatment [abstract].Blood. 1995;86(suppl 434a). Abstract 1721.Google Scholar
  16. 16.
    Kahn SB, Begg CB, Mazza J, et al. Full dose versus attenuated dose daunorubicin, cytosine arabinoside and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in elderly.J Clin Oncol. 1984;2:865–870.CrossRefPubMedGoogle Scholar
  17. 17.
    Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in elderly: assessment of multidrug resistance (MDR1) and cytoge- netics distinguishes biologic subgroups with remarkably distinct response to standard chemotherapy. A Southwest Oncology Group study.Blood. 1997;89:3323–3329.PubMedGoogle Scholar
  18. 18.
    Heuvel-Eibrink MM, Holt B, Boekhorst PAW, et al. MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukemia.Br J Haematol. 1997;99:76–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Johnson PRE, Hunt LP, Liu Yin JA. Prognostic factors in elderly patients with acute myeloid leukemia: development of a model to predict survival.Br J Haematol. 1993;85:300–306.CrossRefPubMedGoogle Scholar
  20. 20.
    Tilly H, Castaigne S, Bordwssoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlym- phocytic leukemia in the elderly.J Clin Oncol. 1990;8:272–279.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Rika Iwakiri
    • 1
  • Masatsugu Ohta
    • 1
  • Michiaki Mikoshiba
    • 1
  • Hisashi Tsutsumi
    • 1
  • Toshiro Kumakawa
    • 1
  • Mayumi Mori
    • 1
  1. 1.Department of HematologyTokyo Metropolitan Geriatric HospitalTokyoJapan

Personalised recommendations